Skip to content

Study · Observational study · n = 73 · 2026

20 results

Comparative Analysis of Efficacy and Safety of the Glucagon-Like-Peptide-1 Receptor Agonists Tirzepatide and Semaglutide in Solid-Organ Transplant Recipients.

El Khatib O, Chiha M, Jarad O, Salloum C, El Baba K, Dajani R, Al Shaqfa S, El Hajj S

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation1 Feb 2026

PMID41808646 (opens in a new tab)DOI10.6002/ect.2025.0180 (opens in a new tab)PepBankPUB-41808646
Publisher pagePubMedAsk about this study
Jump to 20 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

20 results from studies that gave the peptide. 20 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In solid-organ transplant recipients, tirzepatide led to a greater reduction in median triglyceride levels than semaglutide, despite a significantly shorter treatment duration.

    In plain wordsIn people with an organ transplant, tirzepatide lowered triglycerides more than semaglutide, despite a shorter treatment time.

    Peptide
    Tirzepatide
    Outcome
    DecreaseMedian triglyceride reduction versus semaglutide
    Study

    n = 73

    Comparator
    Semaglutide
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Tirzepatide led to a greater reduction in median triglyceride levels compared with semaglutide, despite a significantly shorter treatment duration.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  2. 02HumanObservational studySafety outcome

    In solid-organ transplant recipients, adverse events were more frequent with semaglutide than with tirzepatide, but follow-up length differed between groups.

    In plain wordsIn people with an organ transplant, side effects were more common with semaglutide than tirzepatide, but follow-up times differed.

    Peptide
    Semaglutide
    Outcome
    IncreaseAdverse events overall versus tirzepatide
    Study

    n = 73

    Comparator
    Tirzepatide
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Adverse events were more frequent in the semaglutide group, including gastrointestinal intolerance and infections, despite being confounded by disparities in follow-up duration.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  3. 03HumanObservational studySafety outcome

    In solid-organ transplant recipients, gastrointestinal intolerance was more frequent with semaglutide than with tirzepatide, with unequal follow-up.

    In plain wordsIn people with an organ transplant, stomach and gut side effects were more common with semaglutide than tirzepatide, but follow-up times differed.

    Peptide
    Semaglutide
    Outcome
    IncreaseGastrointestinal intolerance versus tirzepatide
    Study

    n = 73

    Comparator
    Tirzepatide
    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Adverse events were more frequent in the semaglutide group, including gastrointestinal intolerance and infections, despite being confounded by disparities in follow-up duration.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  4. 04HumanObservational studySafety outcome

    In solid-organ transplant recipients, infections were more frequent with semaglutide than with tirzepatide, with unequal follow-up.

    In plain wordsIn people with an organ transplant, infections were more common with semaglutide than tirzepatide, but follow-up times differed.

    Peptide
    Semaglutide
    Outcome
    IncreaseInfections versus tirzepatide
    Study

    n = 73

    Comparator
    Tirzepatide
    Outcome group
    Adverse events · Infection
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Adverse events were more frequent in the semaglutide group, including gastrointestinal intolerance and infections, despite being confounded by disparities in follow-up duration.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  5. 05HumanObservational studyEfficacy outcome

    In solid-organ transplant recipients, semaglutide significantly improved weight.

    In plain wordsIn people with an organ transplant, weight improved with semaglutide in this chart review.

    Peptide
    Semaglutide
    Outcome
    DecreaseWeight change
    Study

    n = 39

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both agents significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  6. 06HumanObservational studyEfficacy outcome

    In solid-organ transplant recipients, semaglutide significantly improved body mass index.

    In plain wordsIn people with an organ transplant, body mass index improved with semaglutide in this chart review.

    Peptide
    Semaglutide
    Outcome
    DecreaseBody mass index change
    Study

    n = 39

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both agents significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  7. 07HumanObservational studyEfficacy outcome

    In solid-organ transplant recipients, semaglutide significantly improved hemoglobin A1c.

    In plain wordsIn people with an organ transplant, long-term blood sugar improved with semaglutide in this chart review.

    Peptide
    Semaglutide
    Outcome
    DecreaseHemoglobin A1c change
    Study

    n = 39

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both agents significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  8. 08HumanObservational studyEfficacy outcome

    In solid-organ transplant recipients, semaglutide significantly improved fasting plasma glucose.

    In plain wordsIn people with an organ transplant, fasting blood sugar improved with semaglutide in this chart review.

    Peptide
    Semaglutide
    Outcome
    DecreaseFasting plasma glucose change
    Study

    n = 39

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both agents significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  9. 09HumanObservational studyEfficacy outcome

    In solid-organ transplant recipients, semaglutide significantly improved triglyceride levels.

    In plain wordsIn people with an organ transplant, blood triglycerides improved with semaglutide in this chart review.

    Peptide
    Semaglutide
    Outcome
    DecreaseTriglyceride change
    Study

    n = 39

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both agents significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  10. 10HumanObservational studySafety outcome

    In solid-organ transplant recipients, semaglutide was not linked to significant changes in tacrolimus levels.

    In plain wordsIn people with an organ transplant, tacrolimus levels did not change significantly with semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeTacrolimus levels
    Study

    n = 39

    Outcome group
    Adverse events · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant changes in tacrolimus levels, graft function, or mortality were observed in either group.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  11. 11HumanObservational studySafety outcome

    In solid-organ transplant recipients, semaglutide was not linked to significant changes in graft function.

    In plain wordsIn people with an organ transplant, graft function did not change significantly with semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeAllograft function
    Study

    n = 39

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant changes in tacrolimus levels, graft function, or mortality were observed in either group.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  12. 12HumanObservational studySafety outcome

    In solid-organ transplant recipients, semaglutide was not linked to significant changes in mortality.

    In plain wordsIn people with an organ transplant, deaths did not change significantly with semaglutide.

    Peptide
    Semaglutide
    Outcome
    No significant changeMortality
    Study

    n = 39

    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant changes in tacrolimus levels, graft function, or mortality were observed in either group.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  13. 13HumanObservational studyEfficacy outcome

    In solid-organ transplant recipients, tirzepatide significantly improved weight.

    In plain wordsIn people with an organ transplant, weight improved with tirzepatide in this chart review.

    Peptide
    Tirzepatide
    Outcome
    DecreaseWeight change
    Study

    n = 34

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both agents significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  14. 14HumanObservational studyEfficacy outcome

    In solid-organ transplant recipients, tirzepatide significantly improved body mass index.

    In plain wordsIn people with an organ transplant, body mass index improved with tirzepatide in this chart review.

    Peptide
    Tirzepatide
    Outcome
    DecreaseBody mass index change
    Study

    n = 34

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both agents significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  15. 15HumanObservational studyEfficacy outcome

    In solid-organ transplant recipients, tirzepatide significantly improved hemoglobin A1c.

    In plain wordsIn people with an organ transplant, long-term blood sugar improved with tirzepatide in this chart review.

    Peptide
    Tirzepatide
    Outcome
    DecreaseHemoglobin A1c change
    Study

    n = 34

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both agents significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  16. 16HumanObservational studyEfficacy outcome

    In solid-organ transplant recipients, tirzepatide significantly improved fasting plasma glucose.

    In plain wordsIn people with an organ transplant, fasting blood sugar improved with tirzepatide in this chart review.

    Peptide
    Tirzepatide
    Outcome
    DecreaseFasting plasma glucose change
    Study

    n = 34

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both agents significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  17. 17HumanObservational studyEfficacy outcome

    In solid-organ transplant recipients, tirzepatide significantly improved triglyceride levels.

    In plain wordsIn people with an organ transplant, blood triglycerides improved with tirzepatide in this chart review.

    Peptide
    Tirzepatide
    Outcome
    DecreaseTriglyceride change
    Study

    n = 34

    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both agents significantly improved weight, body mass index, hemoglobin A1c, fasting plasma glucose, and triglyceride levels.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  18. 18HumanObservational studySafety outcome

    In solid-organ transplant recipients, tirzepatide was not linked to significant changes in tacrolimus levels.

    In plain wordsIn people with an organ transplant, tacrolimus levels did not change significantly with tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeTacrolimus levels
    Study

    n = 34

    Outcome group
    Adverse events · Pharmacology
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant changes in tacrolimus levels, graft function, or mortality were observed in either group.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  19. 19HumanObservational studySafety outcome

    In solid-organ transplant recipients, tirzepatide was not linked to significant changes in graft function.

    In plain wordsIn people with an organ transplant, graft function did not change significantly with tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeAllograft function
    Study

    n = 34

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant changes in tacrolimus levels, graft function, or mortality were observed in either group.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.
  20. 20HumanObservational studySafety outcome

    In solid-organ transplant recipients, tirzepatide was not linked to significant changes in mortality.

    In plain wordsIn people with an organ transplant, deaths did not change significantly with tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    No significant changeMortality
    Study

    n = 34

    Outcome group
    Mortality · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    No significant changes in tacrolimus levels, graft function, or mortality were observed in either group.
    1 context sentence
    Summary · context
    This retrospective chart review study involved 73 solid-organ transplant recipients treated with semaglutide (n = 39) or tirzepatide (n = 34) at a quaternary care center in the United Arab Emirates.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:07 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.